CERS Cerus Corporation
Cerus Corporation (CERS) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is $0.00 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.5% since its last earnings release on November 2, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Cerus Corporation
Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Sector
Healthcare
Industry
Biotechnology
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.